Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors

BACKGROUND: TKIs are the first-line treatment for patients with Ph-positive (Ph+) leukemia. However, drug resistance is frequently observed, mainly due to mutations within the breakpoint cluster region-Abelson leukemia virus (BCR-ABL) kinase domain. The T315I substitution confers complete resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Peipei, Guo, Dan, Shao, Xiaoyan, Peng, Miaoxin, Chen, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626416/
https://www.ncbi.nlm.nih.gov/pubmed/29026321
http://dx.doi.org/10.2147/OTT.S142482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626416/
https://www.ncbi.nlm.nih.gov/pubmed/29026321
http://dx.doi.org/10.2147/OTT.S142482

Ejemplares similares